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Vaspin and omentin: new adipokines differentially regulated at the site of 
inflammation in rheumatoid arthritis 
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Scientific interest in adipose tissue-derived peptides has increased dramatically in 
recent years (1). Several mediators known as adipo(cyto)kines were first associated with 
the pathophysiology of obesity-related complications; however a significant role for 
adipokines such as leptin, adiponectin, resistin and visfatin in regulating immune 
responses and inflammation has recently been discovered (1, 2). Several reports (3-6) 
have already demonstrated association of these adipokines with the severity of 
rheumatoid arthritis (RA).  
 
Vaspin, a member of the serine protease inhibitor family, and omentin (also 
known as intelectin) were recently identified in adipose tissue (7, 8). Vaspin is an 
adipokine with insulin-sensitizing effects that has been suggested to be a compensatory 
mediator for abrogating obesity and its inflammatory complications (7). Expression of the 
omentin gene was demonstrated in omental adipose tissue of patients with Crohn’s 
disease, suggesting that it may be implicated in chronic inflammatory diseases (8). The 
aim of the present report was to compare local concentrations of vaspin and omentin in 
synovial fluid of RA patients with those in osteoarthritis (OA) patients and to 
characterize their potential association with the severity of the disease.  
 
Synovial fluid was obtained during therapeutic arthrocentesis from 33 patients 
with RA and 33 patients with knee OA. The disease activity of RA patients was assessed 
by DAS28. C-reactive protein (CRP), IgM-rheumatoid factor (RF) and anti-citrullinated 
peptide antibodies (ACPA) were routinely analyzed from peripheral blood obtained at the 
time of arthrocentesis. Characteristics of the patients are given in Table 1. Vaspin 
(AdipoGen Inc. Korea) and omentin (Apotech Corporation) were analyzed in synovial 
fluid by ELISA assays. Ethical approval was obtained from the local Ethics Committee 
and all patients provided informed consent. Statistical analysis was performed using 
GraphPad Prism 5.0 software. To meet a normal distribution, vaspin and omentin 
concentrations were naturaly logarithmically (log)-transformed. Differences between two 
independent parameters were determined by Kruskal-Wallis or T-test. The Spearman test 
was used for correlation of parameters. 
 
As shown in figure 1, the mean (SD) levels of vaspin were significantly higher in 
the synovial fluid of RA patients than in OA patients (-2.439±1.226 vs. -3.366±1.318 
(log) pg/ml; p=0.003), but interestingly the levels of omentin were significantly lower in 
the synovial fluid of RA patients compared to OA patients (1.491±0.948 vs. 1.964±0.902 
(log) ng/ml; p=0.045). After log-transformation, synovial fluid vaspin, but not omentin, 
had a tendency to correlate with DAS28 (r=0.320, p=0.070) in RA patients. However, 
neither vaspin nor omentin correlated with serum CRP or leukocyte counts in synovial 
fluid. In addition, levels of synovial fluid omentin, but not vaspin, significantly correlated 
with serum ACPA (r=0.398, p=0.029) and IgM-RF (r=0.592, p<0.001). The levels of 
synovial fluid vaspin and omentin were not affected by body mass index (BMI) or age of 
the patients. The mean concentration of synovial fluid vaspin, but not omentin, was twice 
as high in female as in male patients, but possibly due to the low number of male patients 
in this study, it failed to reach statistical significance. 
Our data shows different levels of the new adipokines vaspin and omentin at the 
site of local inflammation. We demonstrate here for the first time elevated levels of 
vaspin and reduced levels of omentin in synovial fluid of patients with RA compared 
with those with OA.  
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Table and figure legend 
 
Table 1 Demographic and disease characteristics of the patients. 
Characteristics RA (n=33) OA (n=33) p 
Age (years) 58.9±9.9 65.0±9.9 0.021 
Sex (F/M) 25/8 22/11  0.001 
BMI (kg/m²) 25.5±4.2 28.4±4.3 0.050 
DM 1/33 1/33 - 
DAS28 5.2±1.3 - - 
CRP (mg/l) 25.1±23.8 2.7±2.3  0.001 
RF positivity (%) 60.6 - - 
ACPA positivity (%) 57.6 - - 
DMARD/GC 33*/25 - - 
 
RA, rheumatoid arthritis; OA, osteoarthritis; F, female; M, male; BMI, body mass index; DM, 
diabetes mellitus; DAS, disease activity score; CRP, C-reactive protein; RF, rheumatoid factor; 
ACPA, anti-citrullinated peptide antibodies; DMARD, disease modifying drugs; GC, 
glucocorticoids. DAS28 and CRP are showed as mean±SD. 
* 5 of the 33 patients were treated with TNF inhibitors 
 
 
 
 
Figure 1 Elevated synovial fluid vaspin levels and reduced omentin levels in patients 
with rheumatoid arthritis (RA; left box) in comparison with patients with osteoarthritis 
(OA; right box). Vaspin and omentin levels were natural logarithm (log)-transformed to 
produce a normal distribution. Horizontal solid bars within the box represent the median; 
the boxes represent a range of  25 around the median. Vertical bars indicate 95 
confidence interval. Outliers are indicated.  
 
 
 
